New Ozempic-alternative diabetes pill burns fat without muscle loss, study suggests

Scientists in Sweden have created a new pill designed to help the body burn fat and control blood sugar in a different way than popular GLP- drugs like Ozempic While injectable GLP- s work by suppressing appetite this new medicine boosts metabolism in the muscles A evaluation led by researchers at Karolinska Institutet and Stockholm University included both an early animal assessment and a human clinical trial with healthy adults and people with type diabetes according to a press release NEW WEIGHT-LOSS SHOT SHOWS MAJOR FAT REDUCTION BUT EXPERTS URGE CAUTIONThe new oral medication was identified to successfully control blood glucose boost fat burning and retain muscle mass in animals while getting high marks for tolerability and safety in humans It was also uncovered to have fewer side effects than GLP- s like semaglutides and tirzepatides which are known to cause appetite loss gastrointestinal distress and muscle wasting the researchers noted The experimental medication uses a new form of beta- agonist that benefits muscle function while also avoiding overstimulation of the heart which has been identified as a prospective safety concern of older versions The findings were published this week in the journal Cell WEIGHT-LOSS DRUGS NOW LINKED TO CANCER PROTECTION IN WOMEN MAJOR NEW EVALUATION REVEALSBecause the new oral drug acts via a different mechanism than appetite-suppressing medications it could be used alone or in combination with GLP- s the researchers noted Our results point to a future where we can improve metabolic wellness without losing muscle mass disclosed Tore Bengtsson professor at the Department of Molecular Bioscience at Wenner-Gren Institute Stockholm University in the release Muscles are major in both type diabetes and obesity and muscle mass is also directly correlated with life expectancy This medication has the expected to be of great importance for patients with type diabetes and obesity according to Shane C Wright assistant professor at the Department of Physiology and Pharmacology at Karolinska Institutet CLICK HERE TO SIGN UP FOR OUR PHYSICAL CONDITION NEWSLETTER Our substance appears to promote healthy weight loss and in addition patients do not have to take injections he added Dr Trey Wickham interim chief of the Division of Endocrinology Diabetes Metabolism at VCU Vitality in Richmond Virginia was not involved in the assessment but shared his reaction to the publication in the journal Cell This compound s mechanism of action could address certain specific metabolic concerns with previous weight reduction therapies such as the loss of both muscle and fat tissue Wickham stated Fox News Digital Although the disclosed preliminary results are captivating rigorous testing involving larger longitudinal trials are necessary to ensure human long-term safety and understand the possible role of this compound in the comprehensive evidence-based medicine of obesity and diabetes The review had particular limitations the researchers noted chiefly that the preclinical studies in mice fail to capture the complex nature of these diseases in humans Structural studies are needed to understand exactly how the drug works Our phase material show that compound is well-tolerated however conclusive clinical efficacy input on how the drug controls glucose metabolism are presently still lacking CLICK HERE FOR MORE SOUNDNESS STORIESLooking ahead the company that developed the drug Atrogi AB plans to conduct a larger phase clinical trial with a larger more diverse population including people with obesity TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZThe investigation was supported in part by the Swedish Research Council the Swedish Society for Clinical Research and the Novo Nordisk Foundation Uppsala University University of Copenhagen Monash University and University of Queensland all collaborated with the lead researchers